Accelerating drug discovery and development
Accelerating drug discovery and development

Biomarkers  |  Biosimilars

slide-2
slide-2

Licensing Opportunities

  • Panel of diabetic kidney disease biomarkers validated at high stringency with an antibody platform

Biomarkers

Diagnostics / Prognostics

  • Proven Mass Spectrometry Platforms
  • Discovery for Diabetes, Alzheimer’s, Cancer Markers
  • Cross-Validation with Antibody Platforms
  • Access to Highly Curated Clinical Samples

Analytics
and
Biosimilars

  • Biosimilars / Biologics
  • iTRAQ/TMT
  • Targeted Mass Spectrometry
  • Protein ID
  • Genomics / Metabolomics

Therapeutics

Drug Discovery

  • Accelerated High Throughput Drug Discovery System
  • Native Venom Derived Platform ¬†
  • Antimicrobial / Analgesic Molecules
  • Green Tech Applications

Accredited Laboratory

ISO 17025 quality

Proteomics International has world leading accreditation to ISO/IEC 17025:2005 laboratory standard for provision of proteomics services

  • December 2014

    Proteomics International Laboratories launches new IPO Emerging life science company … Continue reading

    November 2014

    Proteomics International is undertaking an IPO on the ASX. The … Continue reading

    October 2014

    The Department of Industry highlights Medical Technology Innovators in the … Continue reading